19th week of 2010 patent applcation highlights part 39 |
Patent application number | Title | Published |
20100119481 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 2010-05-13 |
20100119482 | Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase - Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods. | 2010-05-13 |
20100119483 | PEPTIDE VIRAL ENTRY INHIBITORS - The present invention provides, inter alia, peptide compositions and methods for treating and preventing Flaviviridae virus (e.g., HCV) infections. | 2010-05-13 |
20100119484 | DERIVATISATION OF BIOLOGICAL MOLECULES - The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula | 2010-05-13 |
20100119485 | NOVEL METHOD FOR BIOLOGICALLY COMBATING THE PROLIFERATION OF LEGIONELLA PNEUMOPHILA, AND NOVEL DISINFECTING AGENT CONTAINING AMOEBIC PROTOZOA OF THE WILLAERTIA GENUS - The invention relates to a method for biologically combating the proliferation of | 2010-05-13 |
20100119486 | ANTIBACTERIAL TREATMENT METHOD - Disclosed is an antibacterial treatment method which has no limitation in the scope of a material to be treated and which enables to reduce the time or cost required for the antibacterial testament. Specifically disclosed is an antibacterial treatment method using an antibacterial agent comprising a powder produced by mixing a microorganism selected from | 2010-05-13 |
20100119487 | CULTURE MEDIUM FOR LACTOBACILLUS ACIDOPHILUS AND STREPTOCOCCUS FAECALIS, COMPOSITION COMPRISING THE SAME AND PREPARATION METHOD THEREOF - The present invention provides a triple vital bacteria composition, including: powder of | 2010-05-13 |
20100119488 | PROBIOTICS TO IMPROVE GUT MICROBIOTA - The use of | 2010-05-13 |
20100119489 | Stimulation of Pancreatic Beta Cell Proliferation - This invention provides a polypeptide, TMEM27, and secreted forms thereof, nucleic acids and constructs encoding the same, and cells comprising the same. The TMEM27 protein is expressed in hormone positive cells at early stages of pancreas development and pancreatic β-cells in the mature pancreas, whose expression promotes pancreatic β-cell replication and increased islet mass. Applications of the protein in diagnostics and therapeutics are described. | 2010-05-13 |
20100119490 | Therapeutic Use of CD31 Expressing Cells - As described below, the present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells. | 2010-05-13 |
20100119491 | DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF - In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity. | 2010-05-13 |
20100119492 | Method and device for activating stem cells - Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells. | 2010-05-13 |
20100119493 | Telencephalic Glial-Restricted Cell Populations and Related Compositions and Methods - Provided herein are telencephalic glial-restricted precursor cell populations and related compositions. Related compositions include, but are not limited to, any cell or cell population derived from a population of telencephalic glial-restricted precursor cells. Further provided are methods of using and producing telencephalic glial-restricted precursor cell populations and related compounds. | 2010-05-13 |
20100119494 | METHODS AND COMPOSITIONS RELATED TO MODULATING THE EXTRACELLULAR STEM CELL ENVIRONMENT - This invention relates, in part, to methods and compositions that modulate the stem cell environment. More specifically, the invention relates, in part, to methods and compositions for modulating stem cell differentiation. Therefore, methods and compositions are provided for modulating glycosaminoglycan moieties, e.g., heparan sulfate glycosaminoglycan (HSGAG) moieties, in the microenvironment of stem cells. Methods and compositions for promoting or inhibiting embryonic stem cell differentiation (e.g., differentiation into endothelial cells) are also provided. This invention also relates, therefore, in part, to cell populations (e.g., endothelial cell populations or impoverished endothelial cell populations) that can be produced with the methods and compositions provided. Furthermore, the invention relates, in part, to tissues, and uses thereof, formed by the methods and compositions provided. Moreover, the invention also relates, in part, to methods of treatment using the methods and compositions provided. | 2010-05-13 |
20100119495 | HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES - The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides. | 2010-05-13 |
20100119496 | ADIPOSE TISSUE DERIVED STROMAL CELLS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present invention relates to a treatment of neural injury and neurodegenerative diseases. Also included in the present invention is the use of adipose tissue derived stromal cells for the treatment of neural injury (stroke, traumatic brain injury, spinal cord injury) and neurodegeneration (i.e. Parkinson's disease). | 2010-05-13 |
20100119497 | PROBIOTICS TO REDUCE EPISODES OF DIARRHOEA IN INFANTS BORN BY CAESAREAN SECTION - The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for preventing or treating diarrhoea in infants delivered by caesarean section. | 2010-05-13 |
20100119498 | DIETARY SUPPLEMENT FOR PROMOTING WELLNESS AND WEIGHT LOSS AND METHODS OF ADMINISTERING THE SAME - Disclosed herein are dietary supplements for promoting wellness and weight loss in a subject. In one aspect, the method includes administering to a subject whom wishes to lose weight a dietary supplement containing an extract product of | 2010-05-13 |
20100119499 | STILBENE-BASED COMPOSITIONS AND METHODS OF USE THEREFOR - Disclosed are compositions, formulations and methods relating to one or more stilbene-based compounds for use in humans. In particular, compositions and formulations comprising an effective amount of the stilbene-based insulinogenic compound can improve athletic performance, lower blood glucose levels, and increase lean muscle mass when administered (e.g., orally) to a human. | 2010-05-13 |
20100119500 | METHOD FOR PREPARING SILICA COMPOSITIONS, SILICA COMPOSITIONS AND USES THEREOF - A method for producing a flowing silica composition including a sol-gel transfer, where redispersion is carried out. The redispersion includes adding, after having reached gel point of the sol-gel transfer, liquid into the gel formed by the sol-gel transfer, and the addition being made within a sufficiently short time period after reaching the gel point, to result, after mixing of the gel and the liquid, in a rheologically homogenous flowing silica composition, which is and remains injectable as such, or by short stirring <30 s, through a thin 22 G needle. Also disclosed are flowing silica compositions and gels obtainable by methods of the invention, and uses of flowing silica compositions. | 2010-05-13 |
20100119501 | METHOD OF DELIVERING A PROTEIN INTO A CELL - There is presently provided a complex of a micelle formed from a cationic polymer and a protein, and a method using the complex to deliver the protein into a cell. | 2010-05-13 |
20100119502 | THERAPY REGIMENS, DOSING REGIMENS AND STABLE MEDICAMENTS FOR THE TREATMENT OF POMPE DISEASE - The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation. | 2010-05-13 |
20100119503 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS - The present invention is directed to compounds of Formula I: | 2010-05-13 |
20100119504 | Marker Sequences for Labour - The invention relates to markers which find use in the diagnosis of labour or pre-term labour, to assays comprising such markers, to methods of identifying therapeutic agents which can prolong pregnancy, using these markers and to methods of treatment of pre-term labour, methods of prolonging gestation, or methods of suppressing labour contractility based on the markers. | 2010-05-13 |
20100119505 | Estrogen Related Receptor, ERRalpha, A Regulator of Bone Formation - Methods and pharmaceutical compositions are provided for modulating bone formation in a mammal. Methods are also provided for screening compounds for their efficacy as modulators of bone formation. | 2010-05-13 |
20100119506 | Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation - The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation. | 2010-05-13 |
20100119507 | STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS - The present invention relates to antigens, more particularly antigenS of | 2010-05-13 |
20100119508 | PHENYLACETIC ACID INHIBITORS OF CYCLOOXYGENASE - The present invention relates to new phenylacetic acid inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-13 |
20100119509 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE DEVELOPMENT OF RHEUMATOID ARTHRITIS - The present invention is directed to polynucleotides encoding polypeptides associated with the development of rheumatoid arthritis and homologs thereof. The invention further relates to diagnostic and therapeutic methods for utilizing these polynucleotides and polypeptides in the diagnosis, treatment, and/or prevention of rheumatoid arthritis and related disease states. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention, and compounds identified thereby. | 2010-05-13 |
20100119510 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS - The present application describes lactam-containing compounds and derivatives thereof of Formula I: | 2010-05-13 |
20100119511 | LIGHT TARGETING MOLECULES AND USES THEREOF - LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided. | 2010-05-13 |
20100119512 | METHODS OF DIAGNOSING, TREATING, AND PREVENTING INCREASED VASCULAR PERMEABILITY - The present invention provides methods for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema. | 2010-05-13 |
20100119513 | Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof - The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment by utilizing the DNA and/or protein disclosed herein. | 2010-05-13 |
20100119514 | Antibodies Against Cancer - An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitising a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate. | 2010-05-13 |
20100119515 | PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS - Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors. | 2010-05-13 |
20100119516 | ANTI-TGF-BETA RECEPTOR II ANTIBODIES - The present invention is directed to antibodies against human transforming growth factor beta receptor II (TGFβRII), pharmaceutical compositions comprising antibodies and methods of using the antibodies, alone or in combination, for example, for treating cancer and fibrosis. | 2010-05-13 |
20100119517 | Use of Anti-MAdCAM Antibodies for the Treatment of Coeliac Disease and Tropical Sprue - Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue The application relates to the use of an anti-MAdCAM antibody for the manufacture of a medicament for the treatment of coeliac disease and/or tropical sprue. Methods of treatment for coeliac disease and/or tropical sprue using a therapeutically effective amount of an anti-MAdCAM antibody are also included. | 2010-05-13 |
20100119518 | TARGET FOR BREAST CANCER THERAPY AND/OR DIAGNOSIS - The present invention relates to breast cancer and methods for identifying therapeutics and diagnosis. In general, methods for identifying therapeutic agents directed to calcium flow arc disclosed. Also provided arc methods for diagnosis of breast cancer and/or a predisposition to breast cancer and methods of treatment of breast cancer. The methods include identifying therapeutic agents which modulate a CRAC channel and/or a glycoprotein activator of a CRAC channel. Also provided arc diagnostic methods that ultilise a CRAC channel and/or a glycoprotein activator of a CRAC channel. | 2010-05-13 |
20100119519 | OPHTHALMIC DRUG DELIVERY SYSTEM AND METHOD - An ocular device comprising a delivery body configured for implanting within the capsular bag of a patient's eye, the delivery body containing an ocular therapeutic agent, the delivery body having a permeable exterior surface for delivering the therapeutic agent when implanted in the patient's eye. | 2010-05-13 |
20100119520 | MONOCLONAL ANTIBODIES THAT NEUTRALIZE ANTHRAX TOXINS - The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2010-05-13 |
20100119521 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY MODULATING HER-2 AND EGF RECEPTORS - An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression. For both p185HER-2 and the EGF receptor, the extent of inhibition was affected by the expression levels of herstatin relative to the receptor. Herstatin is an autoinhibitor of p185HER-2 and expands its inhibitory activity to another member of the group I family of receptor tyrosine kinases, the EGF receptor. Herstatin blocked the activated Akt-mediated EGF survival signal, as well as transforming growth factor alpha (TGFα)-mediated EGF receptor activation, survival signal and proliferation signal. Purified recombinant herstatin specifically inhibited human carcinoma cells that over-express HER-2, and was effectively absorbed into the blood of intraperitoneally injected mice, where it was not proteolytically degraded and was present for between one and three hours. | 2010-05-13 |
20100119522 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2010-05-13 |
20100119523 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 2010-05-13 |
20100119524 | ADJUVANTED VACCINE - This invention relates to an immunogenic composition comprising an Orthopoxvirus antigen and an adjuvant, the adjuvant comprises a CPG-motif-containing oligonucleotide, and the therapeutic uses thereof. | 2010-05-13 |
20100119525 | METHOD FOR EXTENDING LONGEVITY USING NPC1L1 ANTAGONISTS - The present invention relates to a method for prolonging longevity using and NPC1L1 antagonist. The present invention also provides a method for reducing weight in an individual who consumes a high-fat diet using an NPC1L1 antagonist. | 2010-05-13 |
20100119526 | DLL4 Signaling Inhibitors and Uses Thereof - DLL4-binding antibodies, specifically antibodies preventing Notch signaling and internalization of DLL4, can: more efficiently than inhibitors only preventing DLL4-mediated Notch-signaling disrupt angiogenesis and pathological processes including tumor growth. | 2010-05-13 |
20100119527 | N-CADHERIN: TARGET FOR CANCER DIAGNOSIS AND THERAPY - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers. | 2010-05-13 |
20100119528 | Transport of Biologically Active Molecules into a Cell, Mitochondrion, or Nucleus - Novel carrier peptides are described, as well as methods of using the carrier peptides to transport biologically active molecules into a cell, mitochondrion, or nucleus, e.g., by formation of a complex of the carrier peptide non-covalently bound to a biologically active molecule. | 2010-05-13 |
20100119529 | ELASTIN-LIKE POLYMER DELIVERY VEHICLES - In invention concerns elastin-like polymer (ELP) drug delivery compositions and methods for the use thereof. In some aspects ELP delivery vehicles may be used to deliver therapeutic drugs such as Hsp90 antagonists. Furthermore, embodiments of the invention concern in vivo delivery with ELP compositions directed to target sites by the application of local hyperthermia therapy. Methods of the invention may have particular utility in the delivery of geldanamycin and related drugs. | 2010-05-13 |
20100119530 | Regulation of TLR Signaling by Complement - This invention provides methods of inducing the production of pro-inflammatory cytokines by activating Toll like Receptor (TLR) and the complement system. This invention further provides vaccines that contain compounds that activate a Toll like Receptor (TLR) and the complement system. | 2010-05-13 |
20100119531 | NUTRICEUTICAL GELS - A nutriceutical food product includes a solid matrix and a liquid combined into a gel. The nutriceutical food product may include an immune modulator, such as transfer factor and/or a nanofraction immune modulator. A fruit component may be included in the nutriceutical food product. The fruit component may include at least one oligoproanthocyanidin-containing fruit, such as acai. | 2010-05-13 |
20100119532 | Composition comprising the N-terminal region of histone H2B of Leishmania - use thereof for inducing an immune response - The invention concerns an immunogenic composition comprising: i) an antigenic polypeptide consisting of a fragment of the protein histone H2B of | 2010-05-13 |
20100119533 | Polynucleotides and Polypeptides Identified by IVIAT Screening and Methods of Use | 2010-05-13 |
20100119534 | MULTICOMPONENT IMMUNOGENIC COMPOSITION FOR THE PREVENTION OF BETA-HEMOLYTIC STREPTOCOCCAL (BHS) DISEASE - A number of β-hemolytic streptococci polynucleotides and polypeptides, particularly | 2010-05-13 |
20100119535 | COMPOSITIONS AND METHODS FOR IMMUNODOMINANT ANTIGENS - Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens ( | 2010-05-13 |
20100119536 | Naturally Processed Measles Virus Peptides From Class II HLA Molecules - A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed. | 2010-05-13 |
20100119537 | TUMOR VACCINE - The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. | 2010-05-13 |
20100119538 | CHIMERIC OSTEOGENIC FACTOR CONTAINING PROTEINS CAPABLE OF INCREASED NUCLEAR LOCALIZATION AND METHODS OF USE THEREOF - Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further, the methods of making such compositions are also provided. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter and optionally a membrane transduction domain of a viral protein. Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. Methods for treating disc disease associated with trauma or disc degeneration are also described. | 2010-05-13 |
20100119539 | VACCINE AGAINST MALARIA, BASED ON THE 200L SUBUNITI OF PLASMODIUM VIVAX MSP1 PROTEIN - A candidate subunit for a vaccine against malaria caused by | 2010-05-13 |
20100119540 | Vaccination Regimen for B-Cell Vaccines - This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto. | 2010-05-13 |
20100119541 | USE OF A VEGETABLE DRUG COMPOSITION IN THE MANUFACTURING OF PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PORTAL HYPERTENSION CAUSED BY HEPATOCIRRHOSIS - Use of a vegetable drug composition in the manufacturing of a pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis, said preparation comprises 25-38% of extract of radix | 2010-05-13 |
20100119542 | FOOD EXTRACTS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES AND SKIN DISEASES AND SKIN DISORDERS - The present invention is directed to N-methylnicotinamide containing food extracts, and their use in treating lipoprotein abnormalities and skin diseases and disorders. | 2010-05-13 |
20100119543 | USE OF SHIGELLA INVAPLEX TO TRANSPORT FUNCTIONAL PROTEINS AND TRANSCRIPTIONALLY ACTIVE NUCLEIC ACIDS ACROSS MAMMALIAN CELL MEMBRANES IN VITRO AND IN VIVO - The in vivo and in vitro use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. The eukaryotic cells include a variety of cell types, e.g. insect, reptile, fish, mammal and tumor cells. The suitable materials for transport include biochemicals such as reporter molecules, antibiotics, biopharmaceuticals and carbohydrates including polysaccharides, lipopolysaccharides, polynucleotides, such as DNA and RNA, and glycoproteins and proteins including antigens, enzymes, antibodies, receptors and hormones. In addition, Invaplex enhances the immune response to DNA vaccines and also can function by itself as a vaccine against shigellosis. | 2010-05-13 |
20100119544 | VACCINE - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from | 2010-05-13 |
20100119545 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 2010-05-13 |
20100119546 | VACCINE AGAINST AFRICAN HORSE SICKNESS VIRUS - The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions. | 2010-05-13 |
20100119547 | Recombinant Parainfluenza Virus Expression Systems And Vaccines - The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens. | 2010-05-13 |
20100119548 | METHOD FOR LIMITING THE GROWTH OF CANCER CELLS USING AN ATTENUATED MEASLES VIRUS - A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 10 | 2010-05-13 |
20100119549 | CHLAMYDIAL ANTIGENS AS REAGENTS FOR DIAGNOSIS AND TREATMENT OF CHLAMYDIAL INFECTION AND DISEASE - The present invention provides | 2010-05-13 |
20100119550 | RECOMBINANT MULTIVALENT VACCINE - The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene. | 2010-05-13 |
20100119551 | Methods and reagents for vaccination which generate a CD8 T cell immune response - New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. | 2010-05-13 |
20100119552 | PURIFICATION OF VACCINIA VIRUSES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY - The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production. | 2010-05-13 |
20100119553 | Helicobacter pylori sialic acid binding adhesin, SabA and sabA - gene - An isolated | 2010-05-13 |
20100119554 | TRANSPLANTS - The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. | 2010-05-13 |
20100119555 | Methods and Compositions for the Treatment and Diagnosis of Cancer - The invention provides methods of treatment of prion disease, cancers and other conditions, the methods comprising administration of an anti- | 2010-05-13 |
20100119556 | METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOGENIC OLIGONUCLEOTIDES - This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided. | 2010-05-13 |
20100119557 | Frozen compositions and methods for piercing a substrate - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-13 |
20100119558 | NGNA COMPOSITIONS AND METHODS OF USE - The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold. | 2010-05-13 |
20100119559 | DOSAGE FORMS OF RISEDRONATE - Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 2010-05-13 |
20100119560 | NANO-EMULSION, THE USE THEREOF, AND PREPARATION METHOD THEREOF - Embodiments of the present invention relate to nanoemulsions, the use thereof and preparation method thereof wherein the nanoemulsion contains a crosspolymer comprising at least one of a polyacrylic acid chain and a derivative of the polyacrylic acid chain; and polyoxypropylene-polyoxyethylene compound. According to one embodiment, the nanoemulsion forms a droplet with a diameter in the range of about 43 nm to about 96 nm. | 2010-05-13 |
20100119561 | Compositions Having a Performance Indicator - Compositions containing a delivery system including polymeric microparticles capable of undergoing a visual change, such as a color change, after application to a substrate are disclosed. The delivery system informs a consumer that the composition has been properly applied and/or has performed its intended function. | 2010-05-13 |
20100119562 | Structured Personal Care Compositions Comprising A Clay - Structured personal care compositions comprising a clay are contemplated, as well as methods for using such compositions. | 2010-05-13 |
20100119563 | SOLID FIBRINOGEN PREPARATION - A fibrinogen preparation is provided which has an improved solubility, may be prepared within a short time and may be used rapidly in clinical set-up. A solid fibrinogen preparation comprising as a main ingredient fibrinogen and further containing the following components: albumin; a nonionic surfactant; a basic amino acid or a salt thereof; and at least two amino acids or a salt thereof selected from an acidic amino acid or a salt thereof and a neutral amino acid or a salt thereof. The solid fibrinogen composition of the present invention may be held on a medical material to form a supporting material holding fibrinogen. Besides, the supporting material holding fibrinogen may be combined with a component comprising as a main ingredient thrombin to provide a fibrin adhesive. | 2010-05-13 |
20100119564 | Guided bone regeneration membrane and manufacturing method thereof - Disclosed is a guided bone regeneration membrane including a novel mechanism that effectively induces a bone reconstruction ability. The mechanism is provided by forming a bi-layered structure of a first nonwoven fabric layer containing a silicon-releasable calcium carbonate and a poly(lactic acid) as principal components and a second nonwoven fabric layer containing a poly(lactic acid) as a principal component; and coating the first nonwoven fabric layer with an apatite. The guided bone regeneration membrane is available by using a nonwoven fabric manufacturing technique through electrospinning and a simulated body fluid soaking technique. | 2010-05-13 |
20100119565 | ANTIMICROBIAL PARTICLES, PROCESS FOR THE PREPARATION THEREOF AND ANTIMICROBIAL COMPOSITION - The object of this invention is to provide antimicrobial particles that can maintain, for a long period of time, antimicrobial activities in particular the antimicrobial activities after they come in contact with tap water. | 2010-05-13 |
20100119566 | USE OF A SYNERGISTIC COMPOSITIONS AS A THERAPEUTIC AGENT OR DISINFECTANT - The invention relates to the use of a composition comprising a vitamin, a metal ion, and a surfactant, as a therapeutic agent or disinfectant. The composition has been known as a decontaminant because the same efficiently decomposes DNA. It has now been possible to demonstrate that the agent has surprisingly good compatibility while having a wide-ranging disinfecting effect and is therefore also suitable for other purposes, e.g., for disinfecting or dressing wounds. | 2010-05-13 |
20100119567 | INSECTICIDAL COMPOSITION AND ARTICLES OBTAINED THEREOF - A material having insecticidal and acaricidal properties comprising:
| 2010-05-13 |
20100119568 | Apparatus and method for transdermal delivery of parathyroid hormone agents - An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member. | 2010-05-13 |
20100119569 | SYSTEMS FOR IMPROVING MATERIAL EXCHANGE WITH AN IMPLANT - A system for implanting a device within a biological target region for exchange of material with the biological target region is provided. The system includes an implantable device and a plurality of precursor cells. The implantable device has at least one recess on a first surface of the device, and a filter configured to allow communication between the at least one recess and an internal portion of the device. The at least one recess is configured to receive the precursor cells and to allow the cells to mature and convert into microvessels disposed along the recesses. | 2010-05-13 |
20100119570 | Solid Pharmaceutical And Vaccine Dose - An elongate body for parenteral injection at low velocity from a device is described. The body has at least one pointed end and comprises at least one active material. In addition, the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50°. A solid vaccine formulation for needle-free parenteral delivery, methods for making the body, packaging of the body and use of the body, packaging and suitable delivery device are also described. | 2010-05-13 |
20100119571 | IMPLANTABLE DEVICES FORMED ON NON-FOULING METHACRYLATE OR ACRYLATE POLYMERS - Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof. | 2010-05-13 |
20100119572 | POLYVINYL ALCOHOL MICROSPHERES, INJECTABLE SOLUTIONS AND THERAPEUTIC USES OF THE SAME - The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present invention relates to a process for producing the polyvinylalcohol microspheres. | 2010-05-13 |
20100119573 | ENDOTHELIUM MIMICKING NANOMATRIX - Disclosed herein are peptide amphiphiles for use in producing a natural endothelium mimicking nanomatrix. The disclosed natural endothelium mimicking nanomatrix can be used to coat medical devices such as vascular stents to promote endothelializaiton and inhibit restenosis and thrombosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2010-05-13 |
20100119574 | Recombinant Gelatins - The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBE monomer sequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications. | 2010-05-13 |
20100119575 | OSTEOGENIC COMPOSITE MATRIX, METHOD FOR THE PRODUCTION THEREOF AND IMPLANT AND SCAFFOLD FOR TISSUE ENGINEERING PROVIDED WITH A COATING FORMED BY SAID OSTEOGENIC COMPOSITE MATRIX - The invention relates to an osteogenic composite matrix consisting of collagen and non-collagen components of an extracellular matrix (ECM-components), to a method for producing said matrix, to a method for producing an implant or a scaffold for tissue engineering which is provided with a coating formed by said osteogenic composite matrix and is used for stimulating and accelerating a hard tissue formation such as, for example. The implant osseointegration in bones. The inventive osteogenic composite matrix comprises a collagen and at least one non-collagen ECM component or the derivatives thereof, wherein the collagen component consists of non-crosslinked collagen fibres produced by fibrillogenesis and the non-collagen ECM component or the derivatives thereof are integrated into said collagen fibres. | 2010-05-13 |
20100119576 | USE OF ONE OR MORE OF THE ELEMENTS FROM THE GROUP YTTRIUM, NEODYMIUM AND ZIRCONIUM, AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN THOSE ELEMENTS - A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells. | 2010-05-13 |
20100119577 | THERAPEUTIC COMPOSITE FOR CARTILAGE DISORDER USING EXTRACELLULAR MATRIX (ECM) SCAFFOLD - The present invention relates to a method for preparing a cell-derived ECM scaffold to which chondrocytes or stem cells are attached, a method for cartilage regeneration by tissue engineering, which comprises using the cell-derived ECM scaffold, and a therapeutic composition for treating cartilage disorder, which contains the ECM scaffold as an effective component. More specifically, the present invention relates to a method for cartilage regeneration by tissue engineering, which comprises transplanting ECM scaffold, having chondrocytes or stem cells attached thereto, into cartilage defects, and a therapeutic composition for treating cartilage disorder, which contains the ECM scaffold, having chondrocytes or stem cells attached thereto, as an effective component. According to the present invention, when the inventive ECM scaffold having chondrocytes or stem cells attached thereto is transplanted into a cartilage defect, mature articular cartilage having the same appearance and characteristics as those of natural cartilage tissue, can be regenerated without side effects such as inflammatory responses. | 2010-05-13 |
20100119578 | EXTRACELLULAR MATRIX MODULATING COATINGS FOR MEDICAL DEVICES - A unique method and coatings are provided to promote/allow early stage tissue encapsulation/endothelization of medical devices while effectively controlling excessive tissue buildup by eluting antiproliferative therapeutic agent within a body of a patient. The method involves using a therapeutic agent that suppresses excessive extracellular matrix proliferation and allows/promotes thin tissue healing/encapsulation/endothelization of the device. Optimized timing of onset of elution to match onset of excessive extracellular matrix proliferation for maximum effectiveness is achieved by delay barrier with biochemical switch. | 2010-05-13 |
20100119579 | DECELLULARIZED LIVER FOR REPAIR OF TISSUE AND TREATMENT OF ORGAN DEFICIENCY - The present invention provides a liver-derived devitalized mammalian parenchymatous tissue composition which includes an interstitial structure of connective tissue which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue. | 2010-05-13 |
20100119580 | SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF - A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube. | 2010-05-13 |